Yuyun Matthew F, Khaw Kay-Tee, Luben Robert, Welch Ailsa, Bingham Sheila, Day Nicholas E, Wareham Nicholas J
Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom.
Am J Epidemiol. 2004 Feb 1;159(3):284-93. doi: 10.1093/aje/kwh037.
Microalbuminuria is associated with an increased risk of cardiovascular and renal disease in patients with diabetes and hypertension. The role of microalbuminuria as a predictor of coronary heart disease (CHD) has not been examined in large general-population cohorts, and its prognostic significance in persons with established CHD is uncertain. The authors examined the relation between microalbuminuria and incident CHD (1993-2002) in a population-based British cohort of 22,368 men and women aged 40-79 years without prevalent baseline CHD and evaluated its prognostic significance in 1,596 participants with baseline CHD. Participants were members of the Norfolk, United Kingdom, component of the European Prospective Investigation into Cancer and Nutrition (the EPIC-Norfolk Study). At baseline, participants were categorized into normoalbuminuria, microalbuminuria, and macroalbuminuria groups. During an average of 6.4 years of follow-up, 800 primary CHD events were registered. The age-adjusted incidence of CHD increased significantly across ordered categories of albuminuria (4.3, 4.4, and 5.6/1,000 person-years across tertiles of normoalbuminuria, 7.1/1,000 person-years for microalbuminuria, and 12.2/1,000 person-years for macroalbuminuria; p for trend < 0.001). The multivariate hazard ratio for incident primary CHD was 1.36 (95% confidence interval (CI): 1.12, 1.64) for microalbuminuria and 1.59 (95% CI: 1.10, 2.37) for macroalbuminuria. Among participants with established baseline CHD, the independent risk of all-cause mortality associated with microalbuminuria was 1.61 (95% CI: 1.19, 2.07). Microalbuminuria may be useful in identifying persons at increased risk of CHD and subsequent death in the general population.
微量白蛋白尿与糖尿病和高血压患者心血管及肾脏疾病风险增加相关。在大型普通人群队列中,尚未研究微量白蛋白尿作为冠心病(CHD)预测指标的作用,其在已确诊冠心病患者中的预后意义也不明确。作者在一个基于人群的英国队列中,研究了22368名年龄在40 - 79岁、无基线冠心病的男性和女性中微量白蛋白尿与新发冠心病(1993 - 2002年)之间的关系,并评估了其在1596名基线冠心病参与者中的预后意义。参与者是欧洲癌症与营养前瞻性调查(EPIC - 诺福克研究)英国诺福克部分的成员。在基线时,参与者被分为正常白蛋白尿、微量白蛋白尿和大量白蛋白尿组。在平均6.4年的随访期间,记录了800例原发性冠心病事件。经年龄调整的冠心病发病率在白蛋白尿的有序类别中显著增加(正常白蛋白尿三分位数分别为4.3、4.4和5.6/1000人年,微量白蛋白尿为7.1/1000人年,大量白蛋白尿为12.2/1000人年;趋势p<0.001)。微量白蛋白尿组新发原发性冠心病的多变量风险比为1.36(95%置信区间(CI):1.12,1.64),大量白蛋白尿组为1.59(95%CI:1.10,2.37)。在基线确诊冠心病的参与者中,与微量白蛋白尿相关的全因死亡独立风险为1.61(95%CI:1.19,2.07)。微量白蛋白尿可能有助于识别普通人群中冠心病及后续死亡风险增加的个体。